Identification of genomic drivers for the therapeutic response of Cabozantinib in patients with metastatic renal cell carcinoma
© 2024. The Author(s)..
PURPOSE: Cabozantinib (CAB) as monotherapy or in combination with immune checkpoint inhibitors is used for systemic treatment of metastatic renal cell carcinoma (mRCC). However, little is known about predictors of treatment response to CAB. For this reason, known genomic drivers were examined to identify potential predictors of treatment response with CAB.
METHODS: Twenty mRCC patients receiving monotherapy (≥ first-line) with CAB were prospectively included. DNA was extracted from archived primary tumors or metastatic tissue. Targeted DNA sequencing was performed using a gene panel including 328 genes (QIAseq Targeted DNA V3 Panel, Qiagen). The variant evaluation was performed using Varsome. The endpoints were treatment-failure-free-survival (TFFS) to CAB.
RESULTS: 26% of patients received systemic RCC treatment as the primary option. Six patients were treated with CAB in first-line (1L) and 12 patients in ≥ 2L. The median follow-up after initiation of systemic treatment was 26.7 months (mo). The PBRM1 (7 alleles), SETD2 (7 alleles), VHL (11 alleles), and CHEK2 (14 alleles) genes were most frequently altered. The median time to TFFS was 10.5 mo (95% confidence interval (CI) 6.2-14.7 mo). There was a longer treatment response to CAB in patients with alterations of the SETD2 gene (SETD2 alteration median TFFS not reached vs. no SETD2 alterations 8.4 mo (95% CI 5.2-11.6 mo); p = 0.024).
CONCLUSION: Pathogenic variant genes may indicate treatment response to systemic therapy in mRCC. Patients with alterations of the SETD2 gene show longer responses to CAB treatment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
|---|---|
| Enthalten in: |
World journal of urology - 42(2024), 1 vom: 22. Feb., Seite 94 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Borkowetz, Angelika [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
1C39JW444G |
|---|
| Anmerkungen: |
Date Completed 23.02.2024 Date Revised 25.02.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00345-024-04783-y |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368761312 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368761312 | ||
| 003 | DE-627 | ||
| 005 | 20240229151724.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240222s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00345-024-04783-y |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1305.xml |
| 035 | |a (DE-627)NLM368761312 | ||
| 035 | |a (NLM)38386122 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Borkowetz, Angelika |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Identification of genomic drivers for the therapeutic response of Cabozantinib in patients with metastatic renal cell carcinoma |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.02.2024 | ||
| 500 | |a Date Revised 25.02.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a PURPOSE: Cabozantinib (CAB) as monotherapy or in combination with immune checkpoint inhibitors is used for systemic treatment of metastatic renal cell carcinoma (mRCC). However, little is known about predictors of treatment response to CAB. For this reason, known genomic drivers were examined to identify potential predictors of treatment response with CAB | ||
| 520 | |a METHODS: Twenty mRCC patients receiving monotherapy (≥ first-line) with CAB were prospectively included. DNA was extracted from archived primary tumors or metastatic tissue. Targeted DNA sequencing was performed using a gene panel including 328 genes (QIAseq Targeted DNA V3 Panel, Qiagen). The variant evaluation was performed using Varsome. The endpoints were treatment-failure-free-survival (TFFS) to CAB | ||
| 520 | |a RESULTS: 26% of patients received systemic RCC treatment as the primary option. Six patients were treated with CAB in first-line (1L) and 12 patients in ≥ 2L. The median follow-up after initiation of systemic treatment was 26.7 months (mo). The PBRM1 (7 alleles), SETD2 (7 alleles), VHL (11 alleles), and CHEK2 (14 alleles) genes were most frequently altered. The median time to TFFS was 10.5 mo (95% confidence interval (CI) 6.2-14.7 mo). There was a longer treatment response to CAB in patients with alterations of the SETD2 gene (SETD2 alteration median TFFS not reached vs. no SETD2 alterations 8.4 mo (95% CI 5.2-11.6 mo); p = 0.024) | ||
| 520 | |a CONCLUSION: Pathogenic variant genes may indicate treatment response to systemic therapy in mRCC. Patients with alterations of the SETD2 gene show longer responses to CAB treatment | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Cabozantinib | |
| 650 | 4 | |a Genomic alterations | |
| 650 | 4 | |a Metastatic renal cell carcinoma | |
| 650 | 7 | |a cabozantinib |2 NLM | |
| 650 | 7 | |a 1C39JW444G |2 NLM | |
| 650 | 7 | |a DNA |2 NLM | |
| 650 | 7 | |a 9007-49-2 |2 NLM | |
| 650 | 7 | |a Anilides |2 NLM | |
| 650 | 7 | |a Pyridines |2 NLM | |
| 700 | 1 | |a Sommer, Ulrich |e verfasserin |4 aut | |
| 700 | 1 | |a Baretton, Gustavo |e verfasserin |4 aut | |
| 700 | 1 | |a Gruellich, Carsten |e verfasserin |4 aut | |
| 700 | 1 | |a Bürk, Björn Thorben |e verfasserin |4 aut | |
| 700 | 1 | |a Erb, Holger H H |e verfasserin |4 aut | |
| 700 | 1 | |a Thomas, Christian |e verfasserin |4 aut | |
| 700 | 0 | |a MORECAB Consortium |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t World journal of urology |d 1988 |g 42(2024), 1 vom: 22. Feb., Seite 94 |w (DE-627)NLM07484959X |x 1433-8726 |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2024 |g number:1 |g day:22 |g month:02 |g pages:94 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00345-024-04783-y |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 42 |j 2024 |e 1 |b 22 |c 02 |h 94 | ||